These findings strongly suggest that targeting Bcl-2, perhaps through small-molecule inhibitors or gene silencing, offers a promising personalized therapeutic approach for aggressive GC, potentially overcoming drug resistance and suppressing metastasis by re-sensitizing cancer cells to apoptotic stimuli and reducing the survival advantage of stem-like cells. Here, BCL2 is linked to gastric cancer.